Health Care Cost

Implementing changes in a health system to promote biosimilar adoption is not easy, but by implementing a program, there could be substantial savings.

New research presented at the American College of Cardiology's 71st Annual Scientific Session & Expo highlights the high costs of heart failure in the United States and the benefits of healthy eating and exercise as preventive measures.

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much as $30 billion.

While the pandemic will have lasting impacts on the US health care market, much of it has bounced back and returned to normal, said Doug Long, MBA, of IQVIA, during the Thursday keynote at the Academy of Managed Care Pharmacy annual meeting.

Although the medication therapy management program in Tennessee's Medicaid population did not reduce costs, some adherence to medication improved and emergency department visits improved.

CMS-1773-P will establish a budget-neutral payment policy to smooth year-to-year changes in the hospice wage index; President Joe Biden pushes for $22 billion in COVID-19 funding from Congress; an FDA advisory panel said there is not enough evidence supporting the efficacy of the amyotrophic lateral sclerosis (ALS) treatment AMX0035.

Patients with severe asthma continue to have residual disease despite initiating treatment with biologics, and severe uncontrolled asthma is associated with higher economic burden compared with controlled asthma, according to 2 posters.

A new FAIR Health white paper containing the fifth annual edition of FH Healthcare Indicators and FH Medical Price Index was released, showing a dramatic increase in telehealth utilization from 2019 to 2020.

An unprecedented level of detail and robustness around interoperability standards is on its way, and on this episode of Managed Care Cast, we speak with Donald Rucker, MD, the former National Coordinator for Health Information Technology in HHS, about what the opportunities and responsibilities for payers are.

President Biden releases the budget for fiscal year 2023; health care spending is projected to hit $6.8 trillion in 2030; rates of prediabetes on the rise in children.

The FDA approved a drug to treat a rare form of childhood epilepsy; uninsured Americans will no longer have access to free COVID-19 tests; a conservation group is suing the Environmental Protection Agency (EPA) over failure to protect rivers from pollution.

The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.

Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.

Coverage of COVID-19 tests and treatment bills halted for uninsured; Moderna low-dose vaccine in children under 6 years of age shows promise in early clinical trial findings; Pfizer recalls blood pressure medications due to potential carcinogen.

The special enrollment period for Affordable Care Act (ACA) coverage has opened to low-income Americans; the FDA approves the first drug for a rare genetic epilepsy disorder; the National Institutes of Health to launch biomarker testing program for pediatric tumors.

On this episode of Managed Care Cast, Teresa Tyson, DNP, MSN, FNP-BC, FAANP, and Paula Hill-Collins, DNP, MSN, FAANP, discuss how The Health Wagon, a free mobile-based and nurse-managed clinic, provides accessible health care to rural residents in Virginia's Appalachian region.

Recent research presented at the 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting examined different aspects of the use of biologics for severe asthma.

Eosinophilic esophagitis (EoE) is triggered by food and in this interview, Colette Romero, whose son has the disease, discusses the financial implications for families, including equity considerations.

While filgrastim biosimilars had substantial uptake, there was low uptake of infliximab biosimilars. In addition, there was a lack of price competition.

Medicare advantage beneficiaries who received care from providers in 2-sided risk payment models had lower rates of acute care use, according to new study findings.

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates.

For most patients who survive COVID-19 hospitalization, out-of-pocket spending within 180 days of discharge is modest. However, 1 in 10 have out-of-pocket spending exceeding $2000.

Full approval by the FDA follows tentative approval for the complex drug delivery advice for asthma and chronic obstructive pulmonary disease (COPD) granted by the FDA last week amid a patent dispute.

On this episode of Managed Care Cast, Anna Forsythe, PharmD, MSc, MBA, vice president of value and access at Cytel, explains the monetary and humanistic costs of conversion therapy among LGBTQ+ populations in the United States.

After years, the biosimilars horizon may be here with valuable opportunities to improve patient outcomes and reduce costs, said Eric Palmer, president and CEO of Evernorth.